Forinvitox: new platform for in vitro tests launched under EU contract

VITROCELL® Systems selected as company of the day on new Forinvitox website

Waldkirch, (PresseBox) - The Forinvitox project was launched under the EU contract no. LSSB-CT-2007-037779 with the goal to provide an international platform of competence on alternative methods and tests.

Right now the following activities are taken place:
- a retrieval of existing, not properly exploited knowledge about in vitro replacement tests
- an analysis of the needs of toxicity tests among end-users
- an inventory of producers of in vitro/in silico toxicity tests

The information from these inventories will be summarised and an identification of the most urgent testing needs will be finished in May-June 2008.

VITROCELL® SYSTEMS offers a large product program of equipment for the in vitro analysis of airborne substances such as gases, nano particles and complex mixtures. The VITROCELL® product range helps to reduce animal testing in the field of e.g. inhalation toxicology. For this purpose human cells or bacteria are cultivated in special exposure modules and then exposed to the test substances at the air/liquid interface. The customers of VITROCELL® are leading medical and environmental research institutes as well as the pharmaceutical and other industries.

Contact details and information:

The Forinvitox project:
Dr. Cecilia Clemedson (Project Coordinator)
Tel: +46-8-621 09 70

Tel: +49-7681-24 100


Solutions for cultivation and exposure.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Mehr Transparenz bei Künstlicher Intelligenz

Künst­li­che In­tel­li­genz (KI), eng­lisch Ar­ti­fi­cial In­tel­li­gen­ce (AI), hat bis­her ein Tran­s­pa­renz­pro­b­lem: Läuft der AI-Ser­vice über­haupt? Was macht der AI-Ser­vice? Wor­auf greift er zu? Spe­zi­el­le Moni­to­ring-Di­ens­te hel­fen bei der Über­wa­chung Künst­li­cher In­tel­li­genz.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.